Research Analysts Issue Forecasts for Immunome Q1 Earnings

Immunome, Inc. (NASDAQ:IMNM) – Investment analysts at HC Wainwright issued their Q1 2027 EPS estimates for Immunome in a report issued on Tuesday, November 10th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of ($0.72) for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for Immunome’s Q2 2027 earnings at ($0.70) EPS, Q3 2027 earnings at ($0.69) EPS and Q4 2027 earnings at ($0.60) EPS.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.14).

Several other brokerages have also recently weighed in on IMNM. Stifel Nicolaus lowered their target price on Immunome from $24.00 to $23.00 and set a “hold” rating for the company in a report on Tuesday. Piper Sandler decreased their price objective on Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Tuesday. Alliance Global Partners began coverage on shares of Immunome in a research note on Monday, September 21st. They issued a “buy” rating and a $32.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of Immunome in a research note on Tuesday, October 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Thursday, October 15th. Fourteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Immunome presently has a consensus rating of “Moderate Buy” and an average price target of $33.85.

Immunome Stock Down 3.7%

IMNM opened at $18.65 on Wednesday. The stock’s fifty day moving average is $21.15 and its two-hundred day moving average is $22.33. The company has a market capitalization of $2.12 billion, a P/E ratio of -7.06 and a beta of 2.68. Immunome has a 52 week low of $16.11 and a 52 week high of $30.06.

Insider Activity at Immunome

In related news, insider Jack Higgins sold 13,200 shares of the company’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $25.32, for a total transaction of $334,224.00. Following the completion of the sale, the insider directly owned 65,050 shares in the company, valued at $1,647,066. This represents a 16.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.21% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMNM. BlackRock Inc. purchased a new stake in shares of Immunome during the second quarter valued at about $186,588,000. Wellington Management Group LLP raised its stake in shares of Immunome by 10.1% during the 2nd quarter. Wellington Management Group LLP now owns 5,210,216 shares of the company’s stock worth $110,404,000 after acquiring an additional 478,239 shares in the last quarter. Primecap Management Co. CA bought a new position in shares of Immunome during the 2nd quarter worth approximately $97,081,000. Readystate Asset Management LP raised its stake in shares of Immunome by 23.3% during the 2nd quarter. Readystate Asset Management LP now owns 1,605,820 shares of the company’s stock worth $34,027,000 after acquiring an additional 303,958 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in Immunome by 285.6% during the first quarter. Bank of America Corp DE now owns 781,607 shares of the company’s stock valued at $17,094,000 after acquiring an additional 578,890 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

More Immunome News

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and forecast quarterly losses of $0.72, $0.70, $0.69 and $0.60 per share for Q1–Q4 2027, respectively. The forecasts indicate continued losses, but the Buy rating is supportive.
• Positive Sentiment: Piper Sandler maintained an Overweight rating and a $30 price target, despite lowering it from $33. Piper Sandler ratings
• Neutral Sentiment: Immunome released its third-quarter results and a business update; the supplied coverage does not detail the update’s contents. Immunome third-quarter results and business update
• Negative Sentiment: Immunome reported a third-quarter loss of $0.76 per share, missing the consensus estimate of a $0.62 loss by $0.14 per share. Immunome earnings press release
• Negative Sentiment: Stifel Nicolaus lowered its price target from $24 to $23 and kept a Hold rating, signaling less upside in its view. Stifel Nicolaus ratings

About Immunome

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.